Company overview
Basic information
Company name
Baltoji biotechnologija, MB
Company code
304072719
VAT code
LT100015362216
Registered address
Vilnius, Viršuliškių g. 41-8, LT-05103
Registration date
2015-07-23
Company age: 11 y. 3 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
None
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Other non-specialised retail sale
Ownership form
Private without foreign capital
Mažoji bendrija "Baltoji biotechnologija"
Company code: 304072719
Address: Vilnius, Viršuliškių g. 41-8, LT-05103
VAT code: LT100015362216
Description
This description was generated by artificial intelligence.
Baltoji biotechnologija, MB (company code 304072719) is an operational private small partnership registered on 23 July 2015. The company is classified as a micro enterprise within the national private non-financial companies sector and is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Governance is described as CEO only. The company is based in Vilnius, at Viršuliškiu g. 41-8, LT-05103, Vilniaus m. sav., Vilniaus apskr. Its stated activity under EVRK code G.47.12.00 is other non-specialised retail sale. Financially, the business reported revenue of EUR 192.6K in 2025, up from EUR 60.1K in 2024 and EUR 51.7K in 2023, reflecting strong year-on-year growth. Net profit in 2025 was EUR 3.6K, compared with EUR 5.4K in 2024 and EUR 199 in 2023, while the 2025 profit margin was 1.9%. At year-end 2025, equity stood at EUR 14.6K, liabilities at EUR 41.7K, and total assets at EUR 56.3K, with long-term assets of EUR 30.7K and short-term assets of EUR 25.6K.
Download a detailed company report
Make confident decisions with all the information about Baltoji biotechnologija, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.